Cancer NetworkOriginal article
<![CDATA[Ubamatamab Yields Responses in Recurrent Low-Grade Serous Ovarian Cancer]]>
Phase 1positiveubamatamabPositive
AI Analysis
Summary
Ubamatamab demonstrated a 73% objective response rate in Phase 1/2 data from 11 heavily pretreated patients with low-grade serous ovarian cancer. The early-stage results suggest potential clinical benefit in this difficult-to-treat patient population.
Clinical Trial Data
Phase
1/2
Primary Endpoint
Met
Patients
11
Outcome Details
73% objective response rate in 11 heavily pretreated patients
Importance:6/10
Sentiment:
0.75
oncologyovarian cancerearly-stage dataPhase 1/2
Read the original article
Published by Cancer Network on October 5, 2026 2:15 PM